Question Title

1. Did this session meet the stated objectives below? (Required.)

  Yes No
Summarize the evidence for emerging biologic and small molecule therapies in IBD, including TL1A antagonists, IL-23 inhibitors, and anti-fibrotic agents, and identify appropriate patient populations for each.
Review current surgical and endoscopic management approaches to ulcerative colitis, integrating multidisciplinary perspectives.
Evaluate the evidence for and against dual biologic therapy in IBD, including patient selection criteria, safety considerations, and monitoring strategies.
Discuss evolving treatment targets and the implications of a treat-to-target strategy for long-term disease management in IBD.

Question Title

2. Did you perceive any degree of commercial or other inappropriate bias during this session? (Required.)

Question Title

3. Please provide a score for the following: (Required.)

  Poor Fair Good Very Good Excellent
Usefulness/Practicality of the presentation
Scientific content of this presentation
Effectiveness of the speaker(s)
Presentation format
Adequate time for questions/discussion

Question Title

4. If you have further feedback or suggestions about this session or the overall summit, please add it below.

T